AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery vehicles behind mRNA therapies like the COVID-19 vaccines, have been much more limited.

Designing LNPs is especially challenging: Each formulation combines multiple lipid components whose ratios influence how the particle delivers genetic instructions inside cells. Scientists still lack a clear map connecting those chemical inputs to biological outcomes.

The reason? There simply isn’t enough data.